Free Trial

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 629.69 +13.69 (+2.22%)
As of 08:11 AM Eastern

IBT vs. APEO, MUT, ESCT, TFIF, SLPE, MRCH, NBPE, AGT.LN, JESC, and SDP

Should you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include abrdn Private Equity Opportunities (APEO), Murray Income Trust (MUT), The European Smaller Companies Trust (ESCT), TwentyFour Income (TFIF), Standard Life Private Equity Trust (SLPE), The Merchants Trust (MRCH), NB Private Equity Partners (NBPE), AVI Global Trust (AGT.LN), JPMorgan European Smaller Companies Trust (JESC), and Schroder Investment Trust - Schroder AsiaPacific Fund (SDP). These companies are all part of the "asset management" industry.

International Biotechnology vs. Its Competitors

abrdn Private Equity Opportunities (LON:APEO) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

International Biotechnology has a net margin of 90.66% compared to abrdn Private Equity Opportunities' net margin of 76.01%. International Biotechnology's return on equity of 13.67% beat abrdn Private Equity Opportunities' return on equity.

Company Net Margins Return on Equity Return on Assets
abrdn Private Equity Opportunities76.01% 5.18% 3.35%
International Biotechnology 90.66%13.67%3.57%

72.2% of abrdn Private Equity Opportunities shares are held by institutional investors. Comparatively, 45.2% of International Biotechnology shares are held by institutional investors. 3.7% of abrdn Private Equity Opportunities shares are held by company insiders. Comparatively, 4.2% of International Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, abrdn Private Equity Opportunities' average media sentiment score of 0.00 equaled International Biotechnology'saverage media sentiment score.

Company Overall Sentiment
abrdn Private Equity Opportunities Neutral
International Biotechnology Neutral

abrdn Private Equity Opportunities has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, International Biotechnology has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.

abrdn Private Equity Opportunities pays an annual dividend of GBX 17 per share. International Biotechnology pays an annual dividend of GBX 29 per share and has a dividend yield of 4.6%. abrdn Private Equity Opportunities pays out 4,250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. International Biotechnology pays out 27.7% of its earnings in the form of a dividend. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

abrdn Private Equity Opportunities has higher revenue and earnings than International Biotechnology. abrdn Private Equity Opportunities is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
abrdn Private Equity Opportunities£80.21M0.00£60.96M£0.40N/A
International Biotechnology£41.82M5.41£37.91M£104.806.01

Summary

International Biotechnology beats abrdn Private Equity Opportunities on 7 of the 12 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

MetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON Exchange
Market Cap£226.19M£1.25B£6.13B£3.00B
Dividend Yield4.20%4.37%4.20%5.02%
P/E Ratio6.0121.9913.00149.03
Price / Sales5.412,404.011,767.47240,012.24
Price / Cash155.7460.81128.0927.97
Price / Book0.821.221.924.60
Net Income£37.91M£263.98M£1.23B£5.90B
7 Day Performance7.46%0.68%0.89%7.40%
1 Month Performance-0.37%2.84%3.22%11.23%
1 Year Performance-4.88%6.24%16.09%81.86%

International Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 629.69
+2.2%
N/A-5.5%£226.19M£41.82M6.01N/A
APEO
abrdn Private Equity Opportunities
N/AN/AN/AN/A£880.29M£80.21M1,435.00N/A
MUT
Murray Income Trust
N/AGBX 875.07
+0.1%
N/A+0.8%£874.27M£97.96M9.64147,000Dividend Cut
ESCT
The European Smaller Companies Trust
N/AGBX 216
+0.2%
N/A+18.0%£851.99M£96.24M10.18305Positive News
TFIF
TwentyFour Income
N/AGBX 113.41
+0.2%
N/A+7.4%£848.90M£55.96M0.98N/ANews Coverage
SLPE
Standard Life Private Equity Trust
N/AGBX 550
flat
N/A+0.0%£845.60M£251.60M3.54N/A
MRCH
The Merchants Trust
N/AGBX 566.05
+0.2%
N/A-2.2%£841.89M£119.93M7.73N/ANews Coverage
Insider Trade
NBPE
NB Private Equity Partners
N/AGBX 1,432
flat
N/A-11.6%£830.57M£12.90M-37.56N/A
AGT.LN
AVI Global Trust
N/AN/AN/AN/A£812.93M£51.62M20.82N/AHigh Trading Volume
JESC
JPMorgan European Smaller Companies Trust
N/AN/AN/AN/A£795.72M£114.05M7.60N/A
SDP
Schroder Investment Trust - Schroder AsiaPacific Fund
N/AGBX 562
-0.4%
N/A+3.1%£793.92M£134.70M6.56N/A

Related Companies and Tools


This page (LON:IBT) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners